Heart failure & cardiomyopathies
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial
Study context
- Population
- Symptomatic adults (≥40 years) with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40% (NYHA II–IV, structural heart disease, diuretic use, elevated natriuretic peptides), hospitalized or ambulatory
- Participants
- 6,001 adults37 countries
- Planned comparison
- Finerenone vs placebo
- Primary endpoint
- Composite of:
- CV death
- Total (first and recurrent) HF events
Methodological detailsrationale and design, global, multicentre, event-driven, placebo-controlled, Started 14 September 2020, ≈2375 total primary composite events targeted, Key exclusions: eGFR <25 ml/min/1.73 m² or serum potassium >5.0 mmol/L
- Rationale and design
- Global
- Multicentre
- Event-driven
- Placebo-controlled
- Started 14 September 2020
- ≈2375 total primary composite events targeted
- Key exclusions: eGFR <25 ml/min/1.73 m² or serum potassium >5.0 mmol/L
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial. Eur J Heart Fail. Published 14 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →